2025-523562-24-00招募中1 期
A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a single dose of REGN22044 in Healthy Adults
Regeneron Pharmaceuticals Inc.1 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2026年5月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 64
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Medical Affairs
Scientific
Regeneron Pharmaceuticals Inc.
研究点 (1)
Loading locations...
相似试验
招募中
1 期
First-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of VTX-PID in healthy male volunteers2023-503892-83-00Vivet Therapeutics35
已完成
1 期
A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS120, which is an Antibody medication, to be administered alone or with Pembrolizumab in Subjects with Advanced Malignancies2024-514777-22-00Invox Pharma Limited113
招募中
1 期
A first-in-human study to determine the safety and tolerability of different doses of GEH200520 Injection and GEH200521 (18F) Injection and their uses in positron emission tomography imaging for patients with cancer2024-515218-42-00GE Healthcare Limited50
招募中
1 期
A First-in-human Study to Evaluate the Safety and Anticancer Effect of Several Doses of TH9619 in Patients with Advanced Cancer (ODIN).2024-519639-40-00One-carbon Therapeutics AB33
招募中
1 期
Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants with MAGE-A4 Expressing Solid Tumors2023-508808-38-00CDR-Life AG49